Source: PR NEWSWIRE

Press Release: Oxford BioTherapeutics : $1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics Initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukemia

OXFORD, England and BERLIN, November 25, 2014 /PRNewswire/ -- Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Christian Rohlff's photo - Founder & CEO of OBT

Founder & CEO

Christian Rohlff

CEO Approval Rating

86/100

OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more